(Cerasomal-cis-9-cetylmyristoleate)t
Cetyl myristoleate may help to lubricate joints and muscles, softening of tissues and increased pliability. It may help to absorb other nutrients better. It may inhibit 5-lipoxygenase, a mediator of inflammation and regulates prostaglandin balance with an anti-inflammatory effect and reduces mistaken auto-immune responses.
It is used for rheumatoid arthritis (RA), osteoarthritis, systemic lupus erythematosus (SLE), multiple sclerosis (MS), ankylosing spondylitis, Sjogren's syndrome, psoriasis, fibromyalgia and relief of various types of back pain.
Published Clinical Studiescl top
CMO (Cerasomal-cis-9-cetylmyristoleate)
1
Synthesis of cetyl myristoleate and evaluation of its therapeutic efficacy in a murine model of collagen-induced arthritis.
Hunter KW Jr, Gault RA, Stehouwer JS, Tam-Chang SW.
Department of Microbiology, University of Nevada School of Medicine, Reno, NV 89557, USA. khunter@unr.edu
Cetyl myristoleate (CM) was reported by Diehl and May [J Pharm Sci 83 (1994) 296] to block inflammation and prevent adjuvant-induced arthritis in rats. To verify this earlier work, we have synthesized pure CM and tested its anti-arthritic properties in a collagen-induced arthritis model in DBA/1LacJ mice. Multiple intraperitoneal injections of CM in 450 and 900 mg kg(-1) doses resulted in a significantly lower incidence of disease and caused a modest but significant diminution in clinical signs in those mice that developed arthritis. CM administered in daily oral doses of 20 mg kg(-1) also reduced the incidence of arthritis and caused a small reduction in the clinical signs in mice that developed arthritis. Although the protective effect of CM in collagen-induced arthritis observed in the present study was less dramatic than that reported earlier, our results confirm the anti-arthritic properties of pure CM.
PMID: 12526860 [PubMed - indexed for MEDLINE]
Cetylated fatty acids improve knee function in patients with osteoarthritis.2
Hesslink R Jr, Armstrong D 3rd, Nagendran MV, Sreevatsan S, Barathur R.
Hesslink Ventures, San Diego, California, USA.
OBJECTIVE: To determine the benefit of cetylated fatty acids (CFA) on knee range of motion and function in patients with osteoarthritis (OA). METHODS: Sixty-four patients with chronic knee OA were evaluated at baseline and at 30 and 68 days after consuming either placebo (vegetable oil; n = 31) or CFA (Celadrin; n = 33). Evaluations included physician assessment, knee range of motion with goniometry, and the Lequesne Algofunctional Index (LAI). RESULTS: After 68 days, patients treated with CFA exhibited significant (p < 0.001) increase in knee flexion (10.1 degrees) compared to patients given placebo (1.1 degrees). Neither group reported improvement in knee extension. Patient responses to the LAI indicated a significant (p < 0.001) shift towards functional improvement for the CFA group (-5.4 points) after 68 days compared to a modest improvement in the placebo group (-2.1 points). CONCLUSION: Compared to placebo, CFA provides an improvement in knee range of motion and overall function in patients with OA of the knee. CFA may be an alternative to the use of nonsteroidal antiinflammatory drugs for the treatment of OA.
Publication Types:
PMID: 12180734 [PubMed - indexed for MEDLINE]
3
Cetyl myristoleate isolated from Swiss albino mice: an apparent protective agent against adjuvant arthritis in rats.
Diehl HW, May EL.
Department of Pharmacology, Medical College of Virginia, Richmond 23298.
Cetyl myristoleate was isolated from National Institutes of Health, general purpose, Swiss albino mice that were immune to the polyarthritis induced in rats with Freund's adjuvant. This substance, or material synthesized from cetyl alcohol and myristoleic acid, afforded good protection against adjuvant-induced arthritic states in rats. In limited comparisons, cetyl oleate, also found in Swiss albino mice, gave lesser protection, whereas cetyl myristate and cetyl elaidate, the trans-isomer of cetyl oleate, appeared to be virtually ineffective. Dosage of the protective compound as well as the site of injection of Freund's adjuvant was important.
PMID: 8207671 [PubMed - indexed for MEDLINE
4
Effect of a cetylated fatty acid topical cream on functional mobility and quality of life of patients with osteoarthritis.
Kraemer WJ, Ratamess NA, Anderson JM, Maresh CM, Tiberio DP, Joyce ME, Messinger BN, French DN, Rubin MR, Gomez AL, Volek JS, Hesslink R Jr.
Human Performance Laboratory, School of Medicine, University of Connecticut, Storrs, Connecticut 06269-1110, USA. William.Kraemer@uconn.edu
OBJECTIVE: To examine the effect of a topical cream consisting of cetylated fatty acids on functional performance in patients diagnosed with osteoarthritis (OA) of one or both knees. METHODS: Forty patients diagnosed with knee OA were randomly assigned to one of 2 topical treatment groups: (1) cetylated fatty acid (CFA) (n = 20; age 62.7 +/- 11.7 yrs); or (2) placebo group (n = 20; age 64.6 +/- 10.5 yrs). Patients were tested on 3 occasions: (1) baseline (T1), (2) 30 min after initial treatment (T2), and (3) after 30-day treatment of cream application twice per day (T3). Assessments included knee range of motion (ROM), timed "up-and-go" from a chair and stair climbing, medial step-down test, and the unilateral anterior reach. RESULTS: For stair climbing ability and the up-and-go test, significant decreases in time were observed at T2 and T3 compared to T1 in the CFA group only. These differences were significant between groups. Supine ROM of the knees increased at T2 and T3 in CFA group, whereas no difference was observed in the placebo group. For the medial step-down test, significant improvement was observed at T2 and T3 compared to T1 in CFA group. For the unilateral anterior reach, significant improvement was observed for both legs in CFA group and in only the left leg in the placebo group. However, the improvements observed in CFA group were significantly greater than placebo group for both legs. CONCLUSION: Use of a CFA topical cream is an effective treatment for improving knee ROM, ability to ascend/descend stairs, ability to rise from sitting, walk and sit down, and unilateral balance.
Publication Types:
PMID: 15088305 [PubMed - indexed for MEDLINE]
Referencesre